WE SELL NOTHING✳EVERY CLAIM → A PRIMARY SOURCE✳UNKNOWN IS A REAL ANSWER✳NO PRODUCTS · NO PROTOCOLS · NO VENDORS✳WE SELL NOTHING✳EVERY CLAIM → A PRIMARY SOURCE✳UNKNOWN IS A REAL ANSWER✳
← All Claim Checks
Source record · FDA status, trial registry, and published phase 3 research · reviewed August 2, 2026

Published phase 3 evidence is meaningful. It is not FDA approval, and it does not make separate trial populations interchangeable.

Misleading
The circulating claim

“Retatrutide already passed Phase 3, so it is basically FDA-approved.”

What the source record says

Retatrutide now has a published phase 3 diabetes trial. The separate TRIUMPH-1 phase 3 obesity registry is completed but posts no results. It remains investigational and not FDA-approved. Neither record validates an unrelated online product.

Why the claim misleads

A published diabetes trial, a completed obesity registry with no posted results, FDA approval, and online product identity are being collapsed into one milestone.

Correction

Published phase 3 evidence is meaningful. It is not FDA approval, and it does not make separate trial populations interchangeable.

Primary sources
FDA concerns with unapproved GLP-1 drugsOpen source ↗Bajaj et al., 2026 — TRANSCEND-T2D-1Open source ↗ClinicalTrials.gov — TRIUMPH-1Open source ↗Retatrutide library entryOpen source ↗
What changed

Separated the published phase 3 diabetes trial from the completed, no-results-posted TRIUMPH-1 obesity registry.

What would change our answer

An FDA approval action and final labeling would change the approval answer. Direct-comparator results would change only their defined comparison questions.

Version history · 3 entries
  1. v3 · 2026-08-02Removed sponsor-announcement sourcing and limited the TRIUMPH-1 statement to the official completed, no-results-posted registry record.Source ↗
  2. v2 · 2026-07-26Separated the published phase 3 diabetes trial from the separate TRIUMPH-1 obesity record and refreshed the FDA boundary.Source ↗
  3. v1 · 2026-07-16Initial structured record created from the reviewed Claim Check.Source ↗
Boundary: This check evaluates a public claim. It does not assess an individual product or person and is not treatment, dosing, sourcing, or legal advice.